The effect of Baduanjin on intestinal flora in patients with prediabetes mellitus: Study protocol for a randomized controlled trial.

Abstract

BACKGROUND:

The incidence rate of prediabetes is increasing year by year. Prediabetes is a continuous ever fount of diabetes. Diabetes is closely related to intestinal flora imbalance and insulin resistance (IR). Previous studies have proved that Baduanjin can effectively improve the blood glucose and blood lipid of patients, but there is no relevant research on intestinal flora and IR. Therefore, this study focuses on the influence of Baduanjin on intestinal flora of patients with prediabetes, so as to improve the effect of IR, and finally delay or prevent the occurrence of to diabetes mellitus 2 type (T2DM).

METHODS:

This study will recruit 80 patients who meet the diagnostic criteria of prediabetes from Hospital of Chengdu University of traditional Chinese Medicine. Eighty patients will be randomly divided into experimental group and control group, 40 cases in each group. The control group received routine lifestyle intervention, and the experimental group received Baduanjin at least 3 to 5 times a week for a total of 6 months. The researchers monitored the intestinal flora, insulin resistance index, blood glucose, blood lipid, body mass index, and other indicators after 3 months of intervention and 6 months of intervention DISCUSSION:: Based on previous studies, intestinal flora is closely related to the occurrence and development of T2DM-IR. Baduanjin can significantly improve the blood glucose and blood lipid of patients with prediabetes, and has a positive effect on the intestinal flora of the elderly and significantly improve the intestinal microecological balance. This study used randomized controlled trial to explore the control method between Baduanjin and conventional lifestyle, in order to further establish the application of Baduanjin in patients with prediabetes.

TRIAL REGISTRATION:

This trial protocol has been approved by the research hospital and registered in China clinical trial registration center on July 6, 2020 (ChiCTR2000034490).

• Authors: Xiangui Lv, Maoyi Yang, Fang Wang, Yao Wang, Xuedong He, Jing Yi, Liping Wang, Shunqi Liao
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 37 Pg. e22108 (Sep 11 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 32925754 (Publication Type: Clinical Trial Protocol, Journal Article)

Topics

• Adult
• Aged
• China
• Female
• Gastrointestinal Microbiome
• Humans
• Insulin Resistance
• Male
• Middle Aged
• Patient Selection
• Prediabetic State (microbiology, therapy)
• Qigong (methods)
• Sample Size